Participant flow12

How many started, completed or left each group, period by period.

1 to 12 of 12

Period	Milestone	Group	Participants
Overall Study	STARTED	Liraglutide 1.8 mg	996
Overall Study	STARTED	Oral Antidiabetic Drug	995
Overall Study	Treated	Liraglutide 1.8 mg	980
Overall Study	Treated	Oral Antidiabetic Drug	984
Overall Study	Full Analysis Set (FAS)	Liraglutide 1.8 mg	996
Overall Study	Full Analysis Set (FAS)	Oral Antidiabetic Drug	995
Overall Study	Safety Analysis Set (SAS)	Liraglutide 1.8 mg	980
Overall Study	Safety Analysis Set (SAS)	Oral Antidiabetic Drug	984
Overall Study	COMPLETED	Liraglutide 1.8 mg	446
Overall Study	COMPLETED	Oral Antidiabetic Drug	362
Overall Study	NOT COMPLETED	Liraglutide 1.8 mg	550
Overall Study	NOT COMPLETED	Oral Antidiabetic Drug	633

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02730377/flow